OPKO Licensee TESARO Announces Successful Achievement of Primary and All Secondary Endpoints in Third and Final Phase 3 Trial of Rolapitant
[Business Wire] – OPKO Health, Inc. , reported that its licensee, TESARO, Inc. , announced positive top-line results from the third and final Phase 3 trial of rolapitant, an investigational neurokinin-1 receptor antagonist in development for the preventi moreView todays social media effects on OPKView the latest stocks trending across Twitter. Click to view dashboardSee who OPKO is hiring next, […]